BiotechTube

Alendronate 70mg weekly

ApprovedWithdrawn
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Hyperparathyroidism

Conditions

Hyperparathyroidism

Trial Timeline

Jul 1, 2006 → Sep 1, 2009

NCT ID
NCT00359385

About Alendronate 70mg weekly

Alendronate 70mg weekly is a approved stage product being developed by Merck for Hyperparathyroidism. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00359385. Target conditions include Hyperparathyroidism.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00359385ApprovedWithdrawn

Competing Products

20 competing products in Hyperparathyroidism

See all competitors
ProductCompanyStageHype Score
ASP7991 + Cinacalcet + PlaceboAstellas PharmaPhase 2
52
KHK7580 + KRN1493Kyowa KirinPhase 2/3
65
KHK7580Kyowa KirinPhase 1
33
KHK7580Kyowa KirinPhase 1/2
41
KHK7580Kyowa KirinPhase 3
77
KHK7580Kyowa KirinPhase 3
77
Cinacalcet HClKyowa KirinApproved
85
KHK7580 + Cinacalcet HydrochlorideKyowa KirinPhase 3
77
Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493Kyowa KirinPhase 2
52
Paricalcitol + CalcitriolAbbViePre-clinical
23
paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placeboAbbViePhase 3
77
Paricalcitol + CalcifediolAbbVieApproved
85
Paricalcitol + Darbepoetin alfaAbbVieApproved
85
EtelcalcetideAmgenPhase 3
76
Cinacalcet + PlaceboAmgenPhase 2
51
Cinacalcet + PlaceboAmgenPhase 3
76
Etelcalcetide + PlaceboAmgenPhase 1
32
Sensipar (Cinacalcet HCl)AmgenPhase 2
51
AMG 073 + PlaceboAmgenPhase 3
76
cinacalcetAmgenPhase 3
76

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85